My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Danaher Corp (NY:DHR)

184.13 +2.99 (+1.65%)
Streaming Delayed Price Updated: 3:42 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Danaher Corp

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and the reasons why the stocks may be drawing attention. 
Via Benzinga
Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst
BofA upgrades Danaher and Revvity, predicting a mixed but improving outlook for life sciences tools in fiscal year 2025 amid ongoing market challenges. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
What the Options Market Tells Us About Danaher
 
Via Benzinga
What the Options Market Tells Us About Danaher
 
Via Benzinga
Peering Into Danaher's Recent Short Interest
 
Via Benzinga
Inquiry Into Danaher's Competitor Dynamics In Life Sciences Tools &amp; Services Industry
 
Via Benzinga
A Look Into Danaher Inc's Price Over Earnings
 
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,600 Today
 
Via Benzinga
Want to Grow a Passive Income Snowball? Buy These 7 Elite Dividend Growth Stocks.
These seven companies are transforming steady profits into rising passive income streams for investors. 
Via The Motley Fool
Critical Insights From Danaher Analyst Ratings: What You Need To Know
 
Via Benzinga
Danaher's Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating
Danaher posts Q3 sales of $5.79 billion, surpassing expectations. 2024 guidance includes bioprocessing revenue decline and Cepheid respiratory sales of $1.7 billion. 
Via Benzinga
A Closer Look at Danaher's Options Market Dynamics
 
Via Benzinga
Earnings Preview: Danaher
 
Via Benzinga
This Is What Whales Are Betting On Danaher
 
Via Benzinga
Here's How Much You Would Have Made Owning Danaher Stock In The Last 10 Years
 
Via Benzinga
Looking Into Danaher's Recent Short Interest
 
Via Benzinga
Stocks Fall, GM Eyes Best Day In A Year, Gold Breaks Records, Silver Hits 12-Year Highs: What's Driving Markets Tuesday?
Wall Street traded lower for the second consecutive day on Tuesday, as investor sentiment turned cautious with the U.S. presidential election just two weeks away. Concerns over U.S. fiscal policies and... 
Via Benzinga
Life Science Giant Danaher Q3 Earnings: Revenue And EPS Beat, Sticks To Annual Guidance
Danaher posted third-quarter sales of $5.8 billion, surpassing expectations, with growth in life sciences and diagnostics segments, and a 27.5% operating margin. 
Via Benzinga
Hedge Fund Billionaire Daniel Loeb Bets On Trump Win, Singles Out This Recent Buy As Having 'Significant Upside Potential'
Hedge fund manager Daniel Loeb is optimistic about the economy and market and he sees Trump likely retaking White House. 
Via Benzinga
Topics Economy Government
DANAHER CORP (NYSE:DHR) can be considered a quality stock. Here's why.
Why Quality Investors May Find DANAHER CORP (NYSE:DHR) Attractive. 
Via Chartmill
$1000 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Uncovering Noteworthy Technical Analysis Findings for DANAHER CORP (NYSE:DHR).
The technical analysis for DANAHER CORP (NYSE:DHR) is highly positive, with a rating of 8 out of 10, suggesting a potential breakout. 
Via Chartmill
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
Via Investor's Business Daily
Topics Stocks
Danaher Is Poised For 'A Good Year In Bioprocessing': Analyst
Stifel analyst Jacob Johnson says Danaher is poised for a gradual recovery in 2025 and could generate high-single-digit growth. 
Via Benzinga
Spotlight on Danaher: Analyzing the Surge in Options Activity
 
Via Benzinga
Danaher Unusual Options Activity
 
Via Benzinga
Momentum Investing Gives You An Edge, Until It Doesn’t
Since 2020, momentum investing has generated significantly better returns than other strategies. Such is not surprising, given the massive amounts of stimulus injected into the financial system. 
Via Talk Markets
Unpacking the Latest Options Trading Trends in Danaher
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.